Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $1,258,386 — We previously performed codon-pair deoptimization (CPD) of various open reading frames (ORFs) of RSV. This is done by rearranging codons using computer algorithms and de novo gene synthesis to increase the content of normally-underrepresented codon-pairs without changing amino acid coding or overall…
Jiang Zhu · INTERNATIONAL AIDS VACCINE INITIATIVE · 2020 · $292,223 — Project Summary Broadly neutralizing antibodies (bnAbs) recognize conserved epitopes on the envelope glycoprotein (Env) of the human immunodeficiency virus type-1 (HIV-1). Atomic structures of the BG505 SOSIP.664 gp140 trimer have provided a rational framework for Env-based HIV-1 vaccine design. …
Matthew Adrian Coleman · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · 2020 · $361,476 — ABSTRACT Throughout the world Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen. In countries with poor sanitary conditions ocular infections with Ct can result in trachoma, the most frequent cause of preventable blindness worldwide. Based on protection and serolo…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $1,847,653 — The development of a protective and/or therapeutic HIV vaccine has been hampered by unprecedented challenges, primarily due to the unique properties of the HIV-1 envelope (Env) trimer, a cleverly engineered entry machinery that features an extraordinary assortment of immune-evasion tactics, includin…
Frederick Porter · DUKE UNIVERSITY · 2020 · $257,560 — Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 Envelopes This IPCAVD grant seeks to develop and evaluate mRNA as an HIV-1 vaccine platform. Project 2 will oversee the manufacture of two nucleoside-modified mRNAs by current good manufacturi…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $629,514 — The overall goal of the Animal Models Core is to support all programs of the IPCAVD by performing immunization studies in CH58 unmutated common ancestor (UCA) VH + VL knock-in (KI) mice and rhesus macaques, with ALVAC-C vCP2438 prime and modified mRNA encoding trivalent mosaic gp120s for induction o…
CHOWDA VENKATARAVAPPA · NEOVAXSYN, INC. · 2020 · $299,999 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
Peter Deak · UNIVERSITY OF CHICAGO · 2020 · $65,310 — Project Abstract: Dendritic cell (DC) antigen uptake and presentation is a crucial initial step in establishing adaptive immune responses. This project will characterize a small sub-set of DCs, called hyper-responder DCs, which display enhanced antigen uptake, immune activation and potentially initi…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2020 · $796,177 — Abstract A vaccine for prevention of genital herpes is a high public health priority. Herpes vaccines that performed well in rodents have not protected humans; therefore, novel approaches are needed. We propose the following: 1) Set a much higher bar for vaccine efficacy in animal models than used p…
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2020 · $609,757 — ABSTRACT Influenza virus is one of the most important human infectious diseases. The influenza mortality is estimated to be approximately 650,000 per year worldwide, in addition, occasional global pandemics can infect up to 20- 40% of the world's population. Licensed influenza virus vaccines require…
ANNE GOLDFELD · BOSTON CHILDREN'S HOSPITAL · 2020 · $270,500 — Ebola virus (EBOV) and Marburg virus (MARV) are highly lethal hemorrhagic fever viruses of the Filoviridae family of viruses. Currently, there are no effective oral or easily scalable therapies for either virus. Both EBOV and MARV manifest vigorous anti-host evasion strategies focused on blocking th…
Alejandro Castellanos-Gonzalez · UNIVERSITY OF TEXAS MED BR GALVESTON · 2020 · $237,000 — Project Summary/Abstract The World Health Organization reports diarrhea kills around 760,000 children under five every year. Cryptosporidium is a leading cause of diarrhea morbidity and mortality. Therefore novel treatments against this pathogen are urgently needed. The limitations of tools used to …
PAUL JOSEPH UTZ · STANFORD UNIVERSITY · 2020 · $842,000 — 7. Project Summary/Abstract The overarching goal of this New Aim 4 is to test the hypothesis that SARS-CoV-2 (CoV-2) causes autoimmune disease (AI) in a subset of infected patients. Our preliminary studies on 336 COVID-19 samples from 282 COVID19 patients (four COVID-19 cohorts in three geographical…
ANDREW W GRIMSON · CORNELL UNIVERSITY · 2020 · $400,213 — Project Summary /Abstract Neonates are highly susceptible to infection and respond poorly to vaccination for reasons that are not well understood. Based on our published data, we believe that neonates are particularly vulnerable to repeat infections because their naïve CD8+ T cells are intrinsically…
Joseph Patti · AGILVAX, INC. · 2020 · $1,152,921 — Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting can…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2020 · $800,558 — PROJECT SUMMARY Studying Natural SIV Reservoirs and Human Zoonotic Risk, we discovered in the last funding period that certain strains of SIV infecting Old World monkeys and African apes share unexpected antigenic cross- reactivity with HIV-1 in the functionally important V1V2 region of the envelope…
SIMON R BEST · JOHNS HOPKINS UNIVERSITY · 2020 · $195,893 — Dr. Simon Best is a junior faculty member in the Department of Otolaryngology – Head and Neck Surgery at the Johns Hopkins School of Medicine where his clinical practice is dedicated to voice and airway disorders. With the support of this Mentored Career Development Award, Dr. Best seeks to better u…
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2020 · $77,904 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
Christopher Parks · INTERNATIONAL AIDS VACCINE INITIATIVE · 2020 · $2,249,057 — DESCRIPTION (provided by applicant): The overall goal of this HIVRAD consortium is to develop and compare four novel vaccine candidates designed to deliver HIV envelope (Env) trimers mimicking the presentation of Env by HIV infection and ultimately generating broadly neutralizing antibodies (b…
Rebecca Dutch · BOSTON UNIVERSITY MEDICAL CAMPUS · 2020 · $255,651 — SUMMARY Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are major causes of respiratory disease and hospitalization in infants. They are also a significant health concern for the elderly, the immunocompromised and individuals who have underlying lung disorders. RSV and HMPV are bo…